Thought Leadership | Diaceutics

Thought Leadership

Blogs

June 13th, 2019

Researchers at Diaceutics uncovered the need for faster laboratory testing turnaround times (TAT) in an abstract accepted for publication by the European Hematology Association (EHA) for its annual meeting in June 2019. The abstract, entitled “FLT3 Testing in Relapsed Acute Myeloid Leukemia Setting Is Becoming Increasingly Common, But Laboratory Turnaround Times (TAT) May Be a Barrier to Trea...

June 12th, 2019

Thought leaders at Diaceutics make the case for global harmonization of clinical laboratory tests in a peer-reviewed article entitled “Diagnostics Reform and Harmonization of Clinical Laboratory Testing,” released online and ahead of print on May 8, 2019 in the Journal of Molecular Diagnostics. The authors (Schreier et al) review the ongoing national debate in the United States over the dev...

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
Jeff Schreier
Robert Feeney
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that covers diagnostic laboratory tests using Next Generation Sequencing (NGS) for patients with advanced cancer. In addition to covering the FDA-approved FoundationOne CDx™ (F1CDx), CMS is now covering other FDA-approved or cleared companion in vitro diag...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
September 1st, 2017
Liquid biopsy: clearing the barriers to support pharma, labs and patients
There was considerable discussion around liquid biopsy at ASCO 2017 at a time when questions about its clinical utility are still to be addressed. ...

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary

The landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017

This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precisio...

Case Studies

Increasing CDx Test Availability in Labs for New Lung Cancer Treatment Generates Additional US$200m in Revenue

Insight into Testing Environment Drives Patient Acquisition/Reduces Patient Leakage

Education, Raising Awareness and Reducing Test Turnaround Time Increases Number of Patients Treated with New Targeted Therapy

Laboratories – the forgotten stakeholder

“Pathologists and laboratories are often overlooked as key stakeholders by pharma and this factor can have a considerable impact on the uptake of targeted therapies.” This case study considers the role of laboratories in relation to uptake, includ...

Our Thought Leadership

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...

Ebooks

September 29th, 2017
PD-L1: The Story So Far
PD-L1 has been one of the most talked about new biomarkers in the context of targeted therapy. This Ebook looks at the dynamic PD-L1 space and discusses topics such as test availability, integration alongside more established biomarkers, complementary testing and how a suboptimal PD-L1 diagnostic marketplace can lead to lost treatment opportunities.
June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.

Ebooks

June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.
April 4th, 2017
Pharma Readiness for Diagnostic Integration 2017
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. This collection of opinion pieces written for Pharma Readiness for Diagnostic Integration 2017 looks at the key trends likely to shape the pharma/diagnostic interface ...
September 29th, 2017
PD-L1: The Story So Far
PD-L1 has been one of the most talked about new biomarkers in the context of targeted therapy. This Ebook looks at the dynamic PD-L1 space and discusses topics such as test availability, integration alongside more established biomarkers, complementary testing and how a suboptimal PD-L1 diagnostic marketplace can lead to lost treatment opportunities.
June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.
April 4th, 2017
Pharma Readiness for Diagnostic Integration 2017
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. This collection of opinion pieces written for Pharma Readiness for Diagnostic Integration 2017 looks at the key trends likely to shape the pharma/diagnostic interface ...
October 14th, 2016
Personalized Medicine: What Pharma Should Do To Get Ready
An essential component of personalized medicine is diagnostic (Dx) testing, which identifies the right patient for the right drug. The diagnostic industry is growing steadily, but what does it mean for the pharmaceutical industry and how can pharma seize this personalized medicine opportunity?

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
Jeff Schreier
Robert Feeney
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that covers diagnostic laboratory tests using Next Generation Sequencing (NGS) for patients with advanced cancer. In addition to covering the FDA-approved FoundationOne CDx™ (F1CDx), CMS is now covering other FDA-approved or cleared companion in vitro diag...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
September 1st, 2017
Liquid biopsy: clearing the barriers to support pharma, labs and patients
There was considerable discussion around liquid biopsy at ASCO 2017 at a time when questions about its clinical utility are still to be addressed. ...

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary

The landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017

This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precisio...

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019

50% of eligible cancer patients are missing out on potentially life-saving drugs due to the broken diagnostic testing ecosystem. Industry Experts at Diaceutics reveal insights and solutions to the current state of affairs.

March 16th, 2018
PM Readiness Report 2018 Summary

The landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017

This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precisio...

March 24th, 2016
Pharma Readiness for Personalized Medicine Summary Report 2016

This report is a quantitative and qualitative assessment of pharma readiness to operate in a personalized medicine marketplace. It is a summary update to the 2015 Pharma Readiness for Personalized Medicine Report which examined how prepared pharmaceutical companies are for the emerging personalized medicine business model. This report specifically examines the revenue achievements and business ...

Case Studies

Increasing CDx Test Availability in Labs for New Lung Cancer Treatment Generates Additional US$200m in Revenue

Insight into Testing Environment Drives Patient Acquisition/Reduces Patient Leakage

Education, Raising Awareness and Reducing Test Turnaround Time Increases Number of Patients Treated with New Targeted Therapy

Laboratories – the forgotten stakeholder

“Pathologists and laboratories are often overlooked as key stakeholders by pharma and this factor can have a considerable impact on the uptake of targeted therapies.” This case study considers the role of laboratories in relation to uptake, includ...

Blogs

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...